Illumina Valuation
Is ILMN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ILMN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ILMN * (MX$2136) is trading above our estimate of fair value (MX$2135.66)
Significantly Below Fair Value: ILMN * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ILMN *?
Other financial metrics that can be useful for relative valuation.
What is ILMN *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$18.74b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.4x |
Enterprise Value/EBITDA | 59x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ILMN *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.5x | ||
WAT Waters | 6.1x | 4.2% | US$18.6b |
SRT3 Sartorius | 6.7x | 10.2% | €20.0b |
AVTR Avantor | 2.4x | 3.7% | US$16.7b |
MTD Mettler-Toledo International | 6.8x | 3.7% | US$26.3b |
ILMN * Illumina | 4.2x | 7.6% | Mex$18.7b |
Price-To-Sales vs Peers: ILMN * is good value based on its Price-To-Sales Ratio (4.2x) compared to the peer average (5.5x).
Price to Earnings Ratio vs Industry
How does ILMN *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Sales vs Industry: ILMN * is expensive based on its Price-To-Sales Ratio (4.2x) compared to the Global Life Sciences industry average (4x).
Price to Sales Ratio vs Fair Ratio
What is ILMN *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 4.2x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ILMN *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$2,136.00 | Mex$2,728.63 +27.7% | 22.1% | Mex$4,296.65 | Mex$1,698.28 | n/a | 22 |
Apr ’25 | Mex$2,230.00 | Mex$2,670.00 +19.7% | 23.4% | Mex$4,305.19 | Mex$1,418.38 | n/a | 22 |
Mar ’25 | Mex$2,424.99 | Mex$2,718.38 +12.1% | 23.4% | Mex$4,390.80 | Mex$1,446.58 | n/a | 22 |
Feb ’25 | n/a | Mex$2,657.33 0% | 29.8% | Mex$4,443.41 | Mex$1,377.80 | n/a | 24 |
Jan ’25 | n/a | Mex$2,531.51 0% | 32.4% | Mex$4,380.89 | Mex$849.01 | n/a | 24 |
Dec ’24 | Mex$1,839.97 | Mex$2,644.27 +43.7% | 38.1% | Mex$4,483.34 | Mex$862.18 | n/a | 21 |
Nov ’24 | Mex$2,041.00 | Mex$3,586.01 +75.7% | 24.0% | Mex$5,797.97 | Mex$1,823.26 | n/a | 21 |
Oct ’24 | n/a | Mex$3,702.26 0% | 25.4% | Mex$5,543.06 | Mex$1,743.10 | n/a | 21 |
Sep ’24 | Mex$2,676.30 | Mex$3,803.50 +42.1% | 19.2% | Mex$5,422.31 | Mex$2,557.70 | n/a | 21 |
Aug ’24 | Mex$3,208.69 | Mex$4,028.98 +25.6% | 17.7% | Mex$5,490.03 | Mex$2,510.69 | n/a | 20 |
Jul ’24 | Mex$3,225.28 | Mex$4,215.12 +30.7% | 17.5% | Mex$5,782.59 | Mex$2,581.52 | n/a | 19 |
Jun ’24 | Mex$3,502.50 | Mex$4,259.03 +21.6% | 17.7% | Mex$5,856.68 | Mex$2,614.59 | n/a | 19 |
May ’24 | n/a | Mex$4,388.26 0% | 17.5% | Mex$5,988.15 | Mex$2,689.29 | n/a | 19 |
Apr ’24 | n/a | Mex$4,503.16 0% | 16.2% | Mex$5,579.55 | Mex$2,789.78 | Mex$2,230.00 | 20 |
Mar ’24 | n/a | Mex$4,513.62 0% | 16.8% | Mex$5,610.20 | Mex$2,777.33 | Mex$2,424.99 | 20 |
Feb ’24 | Mex$4,004.25 | Mex$4,689.96 +17.1% | 16.2% | Mex$5,648.85 | Mex$3,012.72 | n/a | 20 |
Jan ’24 | Mex$3,683.00 | Mex$5,071.98 +37.7% | 19.4% | Mex$6,929.09 | Mex$3,167.58 | n/a | 18 |
Dec ’23 | n/a | Mex$4,998.29 0% | 19.3% | Mex$6,780.62 | Mex$3,099.71 | Mex$1,839.97 | 16 |
Nov ’23 | n/a | Mex$5,151.74 0% | 18.9% | Mex$6,736.90 | Mex$3,467.52 | Mex$2,041.00 | 16 |
Oct ’23 | n/a | Mex$5,232.42 0% | 21.1% | Mex$7,665.82 | Mex$3,530.31 | n/a | 16 |
Sep ’23 | Mex$4,004.88 | Mex$5,067.63 +26.5% | 25.2% | Mex$7,654.95 | Mex$2,618.80 | Mex$2,676.30 | 16 |
Aug ’23 | n/a | Mex$6,280.25 0% | 30.1% | Mex$9,779.47 | Mex$3,056.09 | Mex$3,208.69 | 16 |
Jul ’23 | n/a | Mex$7,128.88 0% | 20.7% | Mex$10,322.36 | Mex$4,942.82 | Mex$3,225.28 | 16 |
Jun ’23 | Mex$4,634.00 | Mex$7,073.56 +52.6% | 20.7% | Mex$10,245.82 | Mex$4,906.17 | Mex$3,502.50 | 16 |
May ’23 | Mex$6,119.30 | Mex$8,402.81 +37.3% | 14.5% | Mex$11,142.32 | Mex$6,939.17 | n/a | 17 |
Apr ’23 | Mex$7,134.24 | Mex$8,634.61 +21.0% | 14.3% | Mex$11,433.83 | Mex$7,120.72 | n/a | 17 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.